Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity on T cells

Cancer Gene Therapy

Volumn 5, Issue 6, 1998, Pages 401-407

  Mezzanzanica, Delia ^a   Canevari, Silvana ^a   Mazzoni, Alessandra ^a   Figini, Mariangela ^a   Colnaghi, Maria I ^a   Waks, Tova ^b   Schindler, Daniel G ^b   Eshhar, Zelig ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Carbohydrate antigens; Chimeric genes; Lewisy; Single chain Fv; T cells; Tumor immunogene therapy

Indexed keywords

CANCER ANTIBODY; FC RECEPTOR; HYBRID PROTEIN; LEWIS Y ANTIGEN; TUMOR ANTIGEN;

AMINO ACID SEQUENCE; ANIMAL; ANTIBODY SPECIFICITY; ARTICLE; BLOOD GROUP LEWIS SYSTEM; BREAST TUMOR; CELL CULTURE; FEMALE; FLOW CYTOMETRY; GENE TRANSFER; HUMAN; HYBRIDOMA; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOLECULAR GENETICS; MOUSE; NUCLEOTIDE SEQUENCE; OVARY TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN TUMOR; T LYMPHOCYTE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, NEOPLASM; ANTIBODY SPECIFICITY; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; BASE SEQUENCE; BREAST NEOPLASMS; FEMALE; FLOW CYTOMETRY; GENE TRANSFER TECHNIQUES; HUMANS; HYBRIDOMAS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOTHERAPY; LEWIS BLOOD-GROUP SYSTEM; MICE; MOLECULAR SEQUENCE DATA; OVARIAN NEOPLASMS; RECEPTORS, FC; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKIN NEOPLASMS; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 0032201554     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Colnaghi MI, Ménard S, Canevari S. Evolution of the therapeutic use of new monoclonal antibodies. Curr Opin Oncol. 1993;5:1035-1042.
2. Maeda M, Firtel RA. Activation of the mitogen-activated protein kinase ERK2 by the chemoattractant folic acid in dictyostelium. J Biol Chem. 1997;272:23690-23695.
3. Riethmüller G, Schneider-Gädicke E, Johnson JP. Monoclonal antibodies in cancer therapy. Curr Opin Immunol. 1993;5:732-739.
4. Riethmüller G, Schneider-Gädicke E, Schlimok G, et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet. 1994;343:1177-1183.
5. Jain RK. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev. 1990; 9:253-266.
6. Boon T, Coulie PG, Van den Eynde B. Tumor antigens recognized by T cells. Immunol Today. 1997;18:267-268.
7. Gross G, Eshhar Z. Endowing T cells with antibody specificity using chimeric T cell receptor. FASEB J. 1992; 6:3370-3378.
8. Moritz D, Wels W, Mattern J, et al. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc Natl Acad Sci USA. 1994;91: 4318-4322.
9. Hwu P, Shafer GE, Treisman J, et al. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J Exp Med. 1993;178: 361-366.
10. Eshhar Z, Waks T, Gross G, et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ζ subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA. 1993;90:720-724.
11. Hwu P, Yang JC, Cowherd R, et al. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res. 1995;55:3369-3373.
12. Weijtens MEM, Willemsen RA, Valerio D, et al. Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity. J Imnunol. 1996;157:836-843.
13. Altenschmidt U, Kahl R, Moritz D, et al. Cytolysis of tumor cells expressing the neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes. Clin Cancer Res. 1996;2:1001-1008.
14. Eshhar Z, Bach N, Fitzer-Attas CJ, et al. The T-body approach: potential for cancer immunotherapy. Springer Semin Immunopathol. 1996;18:199-209.
15. Hakomori S. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res. 1996;56:5309-5318.
16. y are preferentially expressed on small-cell lung cancer cells as detected by the monoclonal antibody MLuC1. Int J Cancer. 1992;51:225-231.
17. Trail PA, Willner D, Lasch SJ, et al. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science. 1993;261:212-215.
18. Hellström I, Trail P, Siegall C, et al. Immunoconjugates and immunotoxins for therapy of solid tumors. Cancer Chemother Pharmacol. 1996;38 (Suppl):S35-S36.
19. Meuth M. Patterns of mutation in cancer cells. Cancer Surv. 1996;28:33-46.
20. Pai LH, Wittes R, Setser A, et al. Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin. Nat Med. 1996;2:350-353.
21. Paolini R, Renard V, Vivier E, et al. Different roles for the Fc epsilon RI gamma chain as a function of the receptor context. J Exp Med. 1995;181:247-255.
22. Agresti R, Alzani R, Andreola S, et al. Histopathological characterization of a novel monoclonal antibody, MLuC1, reacting with lung carcinomas. Tumori. 1988;74:401-410.
23. Munro S, Pelham HRB. An Hsp-like protein in the ER: identity with the 78-kDa glucose-regulated protein and immunoglobulin heavy chain binding protein. Cell. 1986; 46:291-300.
24. Küster H, Thompson H, Kinet JP. Characterization and expression of the gene for the human Fc receptor γ subunit. definition of a new gene family. J Biol Chem. 1990;265:6448-6452.
25. Eshhar Z, Gross G, Waks T, et al. T-bodies: chimeric receptors with antibody-type specificity. Methods Enzymol. 1995;8:133-142.
26. Griffiths AD, Williams SC, Hartley O. Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J. 1994;13:3245-3260.
27. De Bellis D, Schwartz I. Regulated expression of foreign genes fused to lac: control by glucose levels in growth medium. Nucl Acids Res. 1990;18:1311.
28. Breitling F, Dübel S, Seehaus T, et al. A surface expression vector for antibody screening. Gene. 1991;104:147-153.
29. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA. 1989;86:10024-10028.
30. Mazzoni A, Mezzanzanica D, Jung G, et al. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma. Cancer Res. 1996;56:5443-5449.
31. Agadjanyan M, Luo P, Westerink MAJ, et al. Peptide mimicry of carbohydrate epitopes on human immunodeficiency virus. Nat Biotechnol. 1997;15:547-551.
32. Elkins K, Metcalf ES. Monoclonal antibodies demonstrate multiple epitopes on the O antigens of Salmonella typhiimirium LPS. J Immunol. 1984;133:2255-2260.
33. Greenspan NS, Cooper LJN. Intermolecular cooperativity: a clue to why mice have IgG3? Immunol Today. 1992;13: 164-168.
34. Rheinnecker M, Hardt C, Hag LL, et al. Multivalent antibody fragments with high functional affinity for a tumor-associated carbohydrate antigen. J Immunol. 1996; 157:2989-2997.
35. Valitutti S, Lanzavecchia A. Serial triggering of TCRs: a basis for the sensitivity and specificity of antigen recognition. Immunol Today. 1997;18:299-304.
36. Khazaeli MB, Conry RM, LoBuglio AF. Human immune response to monoclonal antibodies. J Immunother. 1994; 15:42-52.
37. Cai X, Garen A. Anti-melanoma antibodies from melanoma patients immunized with genetically modified autologous tumor cells: selection of specific antibodies from single-chain Fv fusion phage libraries. Proc Natl Acad Sci USA. 1995;92:6537-6541.
38. Figini M, Obici L, Mezzanzanica D, et al. Panning phage antibody libraries on cells: isolation of human Fab fragments against ovarian carcinoma using guided selection. Cancer Res. 1998;58:991-996.